<DOC>
	<DOCNO>NCT01609686</DOCNO>
	<brief_summary>Cardiopulmonary bypass surgery associate extensive blood loss upto 20 % patient . Tranexamic acid ( TXA ) routinely administer antifibrinolytic agent reduces blood loss blood transfusion requirement . However , standard dose TXA patient suffer renal dysfunction undergo cardiopulmonary bypass surgery may lead high blood concentration TXA compare patient normal renal function . Solid phase microextraction ( SPME ) fast simple method measure TXA level . This prospective study cadiac surgical patient undergo cardiopulmonary bypass aim study pharmacokinetics TXA patient renal dysfunction . Two patient group study receive either TXA 50mg/kg bolus BART regimen ( 30 mg/kg , 16 mg/kg/h + 2 mg/kg pump prime ) depend type cardiac surgical procedure bleed risk . Hypothesis : Standard dose TXA use cardiac surgery result high blood concentration TXA patient renal dysfunction compare patient normal renal function .</brief_summary>
	<brief_title>Pharmacokinetics Tranexamic Acid Patients With Varying Renal Function Undergoing Cardiac Surgery With Use Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Cardiac surgical patient 18 year age renal dysfunction ( stage 1 , 2 ,3 , 4 5 Kidney Disease Outcome Quality Initiative classification chronic kidney disease ) All patient 18 year age unable give consent Documented drug allergy tranexamic acid Deep hypothermic circulatory arrest Preexisting coagulopathy Pregnancy Advanced liver disease Renal transplant recipient Concomitant treatment contraceptive , tretinonin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cardiac surgery</keyword>
	<keyword>renal dysfunction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tranexamic acid</keyword>
</DOC>